Inhibition of DNMT1 restores expression of tumor suppression-related genes such as p16 and RGS10 and contributes to reduced cancer cell viability, decreased invasive capability, and enhanced treatment sensitivity [15, 16, 19, 37]. This evidence concerns the gene RGS10 and cancer.